Lab Phone: 404.727.3191
Fax: 404.727.3728
1988, CPGS (Engineering), Certificate of Postgraduate Study (Masters degree), Cambridge University, Cambridge, England
1996, MD, PhD (Neuroscience), University of Michigan, Ann Arbor, MI
Co-Director, Huntington Disease Center of Excellence
1987, Phi Beta Kappa and Alpha Epsilon Delta
1987, General and Departmental Honors, Student Activities Senior Service Award with BA
1988-8, Winston Churchill Foundation Scholarship for advanced study in math, science and engineering, Churchill College, Cambridge University
1988-96, Fellow, Medical Scientist Training Program, University of Michigan Medical School
1993, The Nancy Myers Anderson Summer Fellowship, Parkinson's Disease Foundation
1994, Individual Predoctoral National Research Service Award, NIMH
2002- , Dr. George C. Cotzias Memorial Fellowship, American Parkinson Disease Association
Research Focus:
Laboratory:
- Contribution of mitochondrial dysfunction to selective neurodegeneration
- Interaction of environmental and genetic factors in neurodegenerative disorders
- Glutamate receptor function and excitotoxicity
- Systems neurobiology of degenerative disorders such as Parkinson and Huntington diseases
- Experimental therapeutics for neurodegenerative disorders
Clinical Trials:
2001-02 Site PI, “An open-label extension study of remacemide hydrochloride 300 mg bid in subjects with Huntington’s disease”2001- Site PI, “Pilot Huntington At Risk Observational Study” (PHAROS)
2002- Motor Rater, “Neurobiological Predictors of Huntington's Disease” (PREDICT)
2003-04 Site PI, “A randomized, double-blind, placebo-controlled, study of Tetrabenazine in patients with Huntington’s Disease” (TETRA-HD)
2004- Site PI, “Open-Label 24-Week Extension Study of Tetrabenazine for the Treatment of Huntington’s Chorea”
Active Support
Federal:
K08 Mentored Clinical Scientist Development Award, NINDS, NS044267-01 (PI)
Title: Mitochondrial dysfunction in neurodegenerative disease
Dates: 9/15/02 – 8/31/07
Clinical Trial, Huntington Study Group, NIH/NHGRI/NINDS, 1R01HG02449-01 (Site PI)
Title: Pilot Huntington At Risk Observational Study (PHAROS)
Dates: 7/1/02 – 6/30/07
Clinical Trial, Huntington Study Group, NIH/NINDS, 1R01NS40068-01A1 (Motor Rater)
Title: Neurobiological Predictors of Huntington's Disease (PREDICT)
Dates: 5/31/02 – 5/31/06
Foundation:
Research Grant, American Parkinson Disease Association (PI)
Title: Mitochondrial dysfunction in Parkinson disease
Dates: 9/1/02 - 8/31/05
Pharmaceutical:
Clinical Trial, Prestwick Pharmaceuticals, Inc (Site PI)
Title: Open-Label 24-Week Extension Study of Tetrabenazine for the Treatment of Huntington’s Chorea
Dates: 6/2/04 – 3/01/05
Previous Support
Pharmaceutical:
Clinical Trial, Prestwick Pharmaceuticals, Inc (Site PI)
Title: A Randomized, Double-Blind, Placebo-Controlled, Study of Tetrabenazine in Patients with Huntington’s Disease (TETRA-HD)
Dates: 4/1/03 – 6/1/04
Clinical Trial, AstraZeneca, Inc (Site PI)
Title: An open-label extension study of remacemide hydrochloride 300 mg bid in subjects with Huntington’s disease
Dates: 4/7/00 – 4/30/02
Publications
Okun MS, Crucian GP, Fischer L, Walter BL, Testa CM, Vitek JL, DeLong MR, Hanfelt J, Huang X (2004) Testosterone deficiency in a Parkinson's disease clinic: results of a survey. J Neurol Neurosurg Psychiatry 75(1):165-6.
Testa CM, Sherer TB, Greenamyre JT (2005) Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Molecular Brain Res 134:109-118.
Book Chapters:
Testa, CM (2004) Mitochondria in movement disorders. In Movement Disorders: Neurologic Principles and Practice (Watts RL, Koller WC, eds), pp 61-86 McGraw-Hill, New York.